Department of Pharmaceutics and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
J Microencapsul. 2011;28(1):62-73. doi: 10.3109/02652048.2010.529947.
The aim of this study was developing colon targeted-delivery of budesonide for ulcerative colitis. Microcapsules were prepared using spray drying technique by different drug-to-dextran ratios and three molecular weights (MWs) of polymer. Differential scanning calorimetry, X-ray diffraction (XRD), drug release and loading efficiency of microcapsules were studied. In vivo efficacy of the selected formulation prepared by 1 : 10 drug-to-polymer ratio and dextran with MW 500 000 (D10M500) against acetic acid-induced colitis in rats was evaluated and compared to the control and reference groups (mesalasine and budesonide suspensions). The results showed that D10M500 microcapsules could target the drug to colon and its efficacy in reducing macroscopic damage score was higher than mesalasine suspension. Treatment with D10M500 decreased the scores of crypt damage and total colitis significantly compared to the control group which just received the vehicle and the groups treated with mesalasine and budesonide suspension which could not reduce the colitis parameters significantly.
本研究旨在开发用于溃疡性结肠炎的布地奈德结肠靶向递药系统。采用喷雾干燥技术,通过不同的药物-葡聚糖比和三种聚合物分子量(MW)制备微胶囊。研究了微胶囊的差示扫描量热法、X 射线衍射(XRD)、药物释放和载药量。通过 1:10 的药物-聚合物比和 MW 为 500000 的葡聚糖(D10M500)制备的选定配方对乙酸诱导的大鼠结肠炎的体内疗效进行了评价,并与对照组和参比组(美沙拉嗪和布地奈德混悬剂)进行了比较。结果表明,D10M500 微胶囊可以将药物靶向结肠,其降低宏观损伤评分的疗效高于美沙拉嗪混悬剂。与仅接受载体的对照组以及接受美沙拉嗪和布地奈德混悬剂治疗但不能显著降低结肠炎参数的组相比,D10M500 治疗显著降低了隐窝损伤和总结肠炎的评分。